Vera Therapeutics, Inc.
VERA
$39.96
-$1.21-2.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 144.44% | 155.38% | 125.97% | 91.79% | 72.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.71% | 85.97% | 101.34% | 89.71% | 63.87% |
| Operating Income | -88.71% | -85.97% | -101.34% | -89.71% | -63.87% |
| Income Before Tax | -96.92% | -87.49% | -102.40% | -86.06% | -58.50% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -96.92% | -87.49% | -102.39% | -86.06% | -58.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.92% | -87.49% | -102.39% | -86.06% | -58.50% |
| EBIT | -88.71% | -85.97% | -101.34% | -89.71% | -63.87% |
| EBITDA | -88.55% | -85.77% | -101.16% | -90.54% | -137.89% |
| EPS Basic | -70.12% | -53.30% | -62.35% | -46.52% | -19.86% |
| Normalized Basic EPS | -70.01% | -53.30% | -62.35% | -46.56% | -19.89% |
| EPS Diluted | -70.12% | -53.30% | -62.35% | -46.52% | -19.86% |
| Normalized Diluted EPS | -70.01% | -53.30% | -62.35% | -46.56% | -19.89% |
| Average Basic Shares Outstanding | 16.11% | 22.90% | 24.95% | 27.13% | 29.60% |
| Average Diluted Shares Outstanding | 16.11% | 22.90% | 24.95% | 27.13% | 29.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |